of the cyclization of nitrenium ions generated from N-chloro-
N-methoxy-2-phenylacetamides (3) is highly dependent upon
the substitution pattern of the aromatic ring. Unactivated
systems such as 3a cyclize via the Ar2-6 pathway to form
N-methoxybenzolactams 6 while substrates with a 4-methoxy
substituent, such as 3b, undergo spirocyclization (Ar1-5) and
loss of methanol to form dienones 5.4c Glover has proposed
that the ease with which 2 can be generated and the efficiency
with which they undergo N-arylations is due to the fact that
these ions are stabilized by the neighboring oxygen lone pair
and are therefore sufficiently long-lived to undergo cycliza-
tion.4d
Although the pioneering studies of Kikugawa and Glover
established methods for generating N-alkoxy-N-acylnitrenium
ions and explored their reactivity, there have been surpris-
ingly few applications of these intermediates in synthesis.
Notable exceptions, which all involve Ar2-5/6 cyclizations,
include Kikugawa’s total synthesis of eupolauramine,6
preparation of an oxindole model of gelsemine by Fleming,7
and, more recently, Romero’s elegant use of consecutive
nitrenium ion cyclizations in the preparation of the dopamine
D2 receptor agonist PNU-95666E.8 However, to date, as far
as we are aware, there have been no reports of the successful
application of the nitrenium ion-induced Ar1-5 spirocycliza-
tion to the synthesis of a natural product.9 Our interest in
this area was stimulated by the isolation of several alkaloids,
including TAN1251A (7),10 the immunosuppresant FR901483
(8),11 and the cylindricines12 which all contain a 1-azaspiro-
[4.5]decane skeleton that we believed could be readily
accessed using this nitrenium ion chemistry. The successful
realization of this strategy as applied to the synthesis of (-)-
TAN1251A is the subject of this Letter.
industries, which contain the novel 1,4-diazabicyclo[3.2.1]-
octane skeleton.13 TAN1251A is a selective and highly potent
muscarinic M1 receptor antagonist which inhibits the acet-
ylcholine-induced contraction of Guinea-pig ileum with an
ED50 value of 8.0 nM. Since most currently available
muscarinic antagonists are not selective for the numerous
receptor subtypes, there is considerable interest in M1
selective antagonists as they have therapeutic potential for
gastrointestinal and respiratory indications.14 TAN1251A’s
combination of potent biological activity and structural
novelty has attracted the attention of a number of groups:
racemic and asymmetric total syntheses of 7 have recently
been reported by Kawahara15 and Snider.16 Our retrosynthetic
analysis of TAN1251A is illustrated in Scheme 2. We
Scheme 2. Retrosynthetic Analysis of (-)-TAN1251A (7)
envisioned that azaspirocyclization of L-tyrosine derivative
11 using Kikugawa’s4f method would provide dienone 10
which could then serve as a common platform from which
to launch asymmetric syntheses of both 7 and 8. Recognizing
the importance of an amine protecting group capable of
withstanding the oxidative cyclization conditions, we deemed
methyl carbamate to be ideal since it both tolerates bis-
(trifluoroacetoxy)iodobenzene and would serve as a latent
N-methyl group.17 For our initial foray into this area, we
(9) While this work was in progress, Ciufolini and Sorenson indepen-
dently reported complementary methods for preparing spirocyclic pyrroli-
dinones involving the oxidation of phenolic oxazolines, and amines,
respectively. These transformations involve aryl oxidation and subsequent
trapping rather than the formation of N-acylnitrenium ions: (a) Braun, N.
A.; Ousmer, M.; Bray, J. D.; Bouchu, D.; Peters, K.; Peters, E. M.; Ciufolini,
M. A. J. Org. Chem. 2000, 65, 4397-4408. (b) Scheffler, G.; Seike, H.;
Sorenson, E. J. Angew. Chem., Int. Ed. 2000, 39, 4593-4596.
(10) Shirafuji, H.; Tsubotani, S.; Ishimaru, T.; Harada, S. PCT Int. Appl.
1991, WO 91 13,887; Chem. Abstr. 1992, 116, 39780t.
(11) Sakamoto, K.; Tsujii, E.; Abe, F.; Nakanishi, T.; Yamashita, M.;
Shigematsu, N.; Izumi, S.; Okuhara, M. J. Antibiot. 1996, 49, 37-44.
(12) Blackman, A. J.; Li, C.; Hockless, D. C. R.; Skelton, B. W.; White,
A. H. Tetrahedron 1993, 49, 8645-8656.
(13) Although unprecedented in Nature, 1,4-diazabicyclo[3.2.1]octanes
have been the subject of previous synthetic studies: Hirschfield, A.; Taub,
W. Tetrahedron 1972, 28, 1275-1287. Strum, P. A.; Cory, M.; Henry, D.
W.; Ziegler, J. B.; McCall, J. W. J. Med. Chem. 1977, 20, 1333-1337.
(14) Widzowski, D.; Helander, H. F.; Wu, E. S. C. Drug DiscoVery Today
1997, 2, 341-350.
(15) Nagumo, S.; Nishida, A.; Yamazaki, C.; Murashige, K.; Kawahara,
N. Tetrahedron Lett. 1998, 39, 4493-4496.
(16) Snider, B. B.; Lin, H. Org. Lett. 2000, 2, 643-646.
TAN1251A (7) is a member of a family of alkaloids,
recently isolated from Penicillium thomii RA-89 by Takeda
(4) (a) Glover, S. A.; Goosen, A.; McCleland, C. W.; Schoonraad, J. L.
J. Chem. Soc., Perkin Trans. 1 1984, 2255-2260. (b) Kikugawa, Y.;
Kawase, M. J. Am. Chem. Soc. 1984, 106, 5728-5729 (c) Kawase, M.;
Kitamura, T.; Kikugawa, Y. J. Org. Chem. 1989, 54, 3394-3403. (d)
Glover, S. A.; Scott, A. P. Tetrahedron 1989, 45, 1763-1776. (e) Kikugawa,
Y.; Kawase, M. Chem. Lett. 1990, 581-582. (f) Kikugawa, Y.; Shimada,
M.; Matsumoto, K. Heterocycles 1994, 37, 293-301.
(5) For recent reviews of hypervalent iodine(III) reagents, see: (a) Stang,
P. J.; Zhdankin, V. V. Chem. ReV. 1996, 96, 1123-1178. (b) Varvogolis,
A. HyperValent Iodine in Organic Synthesis; Academic Press: San Diego,
1997. (c) Kitamura, T.; Fujiwara, Y. Org. Prep. Proc. Int. 1997, 29, 409-
458.
(6) Kawase, M.; Miyake, Y.; Sakamoto, T.; Shimada, M.; Kikugawa,
Y. Tetrahedron 1989, 45, 1653-1660.
(7) Fleming, I.; Moses, R. C.; Tercel, M.; Ziv, J. J. Chem. Soc., Perkin
Trans. 1 1991, 617-626.
(8) Romero, A. G.; Darlington, W. H.; McMillan, M. W. J. Org. Chem.
1997, 62, 6582-6587.
1054
Org. Lett., Vol. 3, No. 7, 2001